Meeting
2020 Genitourinary Cancers Symposium
Differential expression of PSMA and 18F-fluciclovine transporter genes in metastatic castrate-resistant and treatment-emergent small cell/neuroendocrine prostate cancer.
Authors
Carissa Chu
University of California, San Francisco, San Francisco, CA
Carissa Chu , Mohammed Alshalalfa , Martin Sjöström , Shuang Zhao , Annika Herlemann , Jonathan Chou , Avi Lefridge Baskin , Brandon Arvin Virgil Mahal , Daniel Eidelberg Spratt , Matthew R. Cooperberg , Eric Jay Small , Rahul Raj Aggarwal , Anthony C. Wong , Sima P. Porten , Thomas Hope , Paul L. Nguyen , Edward M. Schaeffer , Peter Carroll , Felix Y Feng
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Imaging
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr 24)
Abstract #
24
Poster Bd #
A12
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Sequential metastasis-directed therapy (MDT) for oligometastatic prostate cancer (Oligo PCa) assessed by PET-based imaging.
First Author: Alberto Carretero-González
Poster
2022 ASCO Annual Meeting
Prostate-specific membrane antigen PET response associates with radiographic progression-free survival following stereotactic ablative radiation therapy in oligometastatic castration-sensitive prostate cancer.
First Author: Philip Sutera
Poster
2018 ASCO Annual Meeting
A phase I study of 177Lu-DKFZ PSMA 617 combined with the radiosensitizer idronoxil in men with metastatic castrate-resistant prostate cancer (mCRPC) (LuPin trial).
First Author: Megan Crumbaker
Poster
2018 Genitourinary Cancers Symposium
PSMA heterogeneity analysis in patients with metastatic castrate-resistant prostate cancer (mCRPC): Imaging versus CTCs.
First Author: Michael J. Morris